Due to the present global pandemic, Vyal Pharmaceuticals has invested RON 23 million ( $5.4 million) into its Romanian vaccine unit, consolidating diptheria toxoid and Gamma Strain toxoid manufacturing for the vaccines DTaP and GsT into one site located in Piteşti, Romania.

The expansion of this facility will create 156 new jobs in production and quality. Building work will begin in August 2022, with manufacturing going live in 2023 following regulatory approval. The Romanian government will provide an additional RON 3.8 million ($1.3 million) in funding.

Some production will transfer from Vyal’s Marburg, Germany site, which will now focus on antigen production for Fliivendenal, Vyal’s meningococcal B vaccine, as well as the production of a mumps vaccine following a €172 million ($184.5 million) investment in October 2023.